Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

The XPO1-FOXC1-HOX Functional Axis Opens New Therapeutic Avenues to Treat DEK-NUP214 AML Patients

Blood (2023) 142 (Supplement 1): 4302.

https://doi.org/10.1182/blood-2023-174891

Published: 2023

Journal Articles

Identification of Acute Myeloid Leukemia Cell Surface Therapeutic Targets Using Single Cell RNA Sequencing Supported By Surface Proteomics

Blood (2023) 142 (Supplement 1): 163.

https://doi.org/10.1182/blood-2023-186367

Published: 2023

Journal Articles

Identification of a Novel Cyclin K Degrader Molecule with Selective Anti-AML Activity

Deanne Gracias, Céline Moison, Rodrigo Mendoza-Sanchez, Simon Fortier, Simon Girard, Jean-Francois Spinella, Tara Macrae, Bounkham Thavonekham, Rejean Ruel, Josee Hebert, Anne Marinier, Guy Sauvageau

Blood (2022) 140 (Supplement 1): 10684.

https://doi.org/10.1182/blood-2022-166517

Published: 2022

Journal Articles

Disruption of Intracellular Metal Homeostasis As a Vulnerability in SF3B1 Mutated AML

Céline Moison, Deanne Gracias, Julie Schmitt, Simon Girard, Simon Fortier, Isabel Boivin, Jean-Francois Spinella, Tara Macrae, Rejean Ruel, Josee Hebert, Anne Marinier, Guy Sauvageau

Blood (2022) 140 (Supplement 1): 10680–10681.

https://doi.org/10.1182/blood-2022-165235

Published: 2022

Journal Articles

Identification of Novel Antigens for Normal Karyotype Triple Mutated Acute Myeloid Leukemia

Arnaud Metois, Marie-Eve Bordeleau, Louis Theret, Azadeh Hajmirza, Ossama Moujaber, Jean-François Spinella, Jalila Chagraoui, Nadine Mayotte, Isabel Boivin, Eric Audemard, Azer Farah, Véronique Lisi, Eric Bonneil, Pierre Thibault, Guillaume Richard-Carpentier, Vincent-Philippe Lavallée, Josee Hebert, Philippe P Roux, Guy Sauvageau

Blood (2022) 140 (Supplement 1): 11791–11792.

https://doi.org/10.1182/blood-2022-166857

Published: 2022

Journal Articles

Identification of Novel Cell Surface Therapeutic Targets for KMT2A -Rearranged Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 6316–6317.

https://doi.org/10.1182/blood-2022-166769

Published: 2022

Journal Articles

Targeting PLZF Enhances Glucocorticoid Sensitivity in Acute Myeloid Leukemia

Azadeh Hajmirza, Laura Simon, Jalila Chagraoui, Nadine Mayotte, Jean-François Spinella, Tara Macrae, Bernhard Lehnertz, Thierry Bertomeu, Jasmin Coulombe-Huntington, Geneviève Boucher, Sébastien Lemieux, Mike Tyers, Josee Hebert, Guy Sauvageau

Blood (2022) 140 (Supplement 1): 8825–8826.

https://doi.org/10.1182/blood-2022-163685

Published: 2022

Journal Articles

IL1R1 Expression Predicts the Benefit from Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Intermediate-Risk Cytogenetics

Guillaume Richard-Carpentier, Francois Beliveau, Sandrine Lacoste, Jean-Francois Spinella, Michael Vladovsky, Patrick Gendron, Sébastien Lemieux, Vincent-Philippe Lavallee, Guy Sauvageau, Josee Hebert

Blood (2022) 140 (Supplement 1): 6333–6334.

https://doi.org/10.1182/blood-2022-170230

Published: 2022

Journal Articles

Platelet EVs contain an active proteasome involved in protein processing for antigen presentation via MHC-I molecules

Blood (2021) 138 (25): 2607–2620.

https://doi.org/10.1182/blood.2020009957

Published: 2021

Includes: Supplemental data

Journal Articles

Efficacy, Toxicity and Cost of Venetoclax-Based Combinations for the Treatment of Acute Myeloid Leukemia: Real-World Evidence from a Canadian Academic Center

Philippe Bouchard, Annie Brisebois-Boyer, Anne Beaudry, Jean-Francois Berthiaume, Nadia M. Bambace, Léa Bernard, Josee Hebert, Julie Bergeron

Blood (2021) 138 (Supplement 1): 1253.

https://doi.org/10.1182/blood-2021-149967

Published: 2021

Journal Articles

High frequency of germline RUNX1 mutations in patients with RUNX1 -mutated AML

Laura Simon, Jean-François Spinella, Chi-Yuan Yao, Vincent-Philippe Lavallée, Isabel Boivin, Geneviève Boucher, Eric Audemard, Marie-Eve Bordeleau, Sébastien Lemieux, Josée Hébert, Guy Sauvageau

Blood (2020) 135 (21): 1882–1886.

https://doi.org/10.1182/blood.2019003357

Published: 2020

Includes: Supplemental data

Journal Articles

A 9-Gene Expression Signature Identifies Patients with Core-Binding Factor Acute Myeloid Leukemia at High Risk of Relapse after Achieving Complete Remission

Guillaume Richard-Carpentier, MD, Miriam Marquis, PhD, Francois Beliveau, PhD, Guy Sauvageau, MD PhD, Josee Hebert, MD

Blood (2019) 134 (Supplement_1): 1432.

https://doi.org/10.1182/blood-2019-129990

Published: 2019

Journal Articles

Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML

Blood (2019) 134 (3): 263–276.

https://doi.org/10.1182/blood.2018862383

Published: 2019

Includes: Supplemental data

Journal Articles

Genetic Characterization of ABT-199 Sensitivity in Human AML

Marie-Eve Bordeleau, PhD, Richard Bisaillon, PhD, Clarisse Thiollier, PhD, Jana Krosl, PhD, Bernhard Lehnertz, PhD, Vincent-Philippe Lavallee, MD, Tara MacRae, Labelle Caroline, Geneviève Boucher, Isabel Boivin, Giovanni D'Angelo, Sylvie Lavallée, Anne Marinier, PhD, Sébastien Lemieux, PhD, Josée Hébert, MD, Guy Sauvageau, MD, PhD

Blood (2018) 132 (Supplement 1): 283.

https://doi.org/10.1182/blood-2018-99-113062

Published: 2018

Journal Articles

Chemogenomic Profiling of Complex Karyotype AML Reveals a Novel Susceptibility to G2/M Checkpoint Inhibition Mediated By HMGA2 Overexpression

Céline Moison, PhD, Vincent-Philippe Lavallee, MD, Clarisse Thiollier, PhD, Jean-Francois Spinella, PhD, Isabel Boivin, Sébastien Lemieux, PhD, Anne Marinier, PhD, Josée Hébert, MD, Guy Sauvageau, MD, PhD

Blood (2018) 132 (Supplement 1): 3925.

https://doi.org/10.1182/blood-2018-99-111304

Published: 2018

Journal Articles

Apoptotic Blocks in Primary Non-Hodgkin B-Cell Lymphomas Identified By BH3 Profiling

Nathalie A Johnson, MD PhD, Claudia M Wever, PhD, Dominique Geoffrion, BSc, Ghassemian Artin, MD, Brailovski Eugene, Pierre Sesques, MD, Jeremy A. Ryan, SM, Liliana Stoica, Josee Hebert, MD, Tina Petrogiannis-Haliotis, MD PhD, Svetlana Dmitrienko, MD PhD, Frenkiel Saul, MD, German Ott, MD, Annette Staiger, Christian Steidl, MD, David W. Scott, PhD MD, FRACP, FRCPA, Koren Kathleen Mann, PhD, Anthony Letai, MD PhD

Blood (2018) 132 (Supplement 1): 4126.

https://doi.org/10.1182/blood-2018-99-118225

Published: 2018

Journal Articles

Reduced Intensity Conditioned Sibling Transplantation Versus No Transplant in Intermediate or High Risk Acute Myeloid Leukemia: A Prospective Multi-Center Study in Patients 50-70 Years in First Complete Remission and with at Least One Potential Sibling Donor ( ClinTrialGov 00342316 )

Mats Brune, MD PhD, Thomas L. Kiss, MD, Elisabeth Wallhult, RN, Harald Anderson, PhD, Robert Delage, MD, Jürgen Finke, MD, Josee Hebert, MD, Martin Höglund, MD PhD, Ain Kaare, MD, Vladimir Lazarevic, MD PhD, Malin Nicklasson, MSc, Kari Remes, MD PhD, David Ritchie, MBChB, PhD FRACP, FRCPA, Mitchell Sabloff, MD, Ruth Spearing, MD, Alexandros Spyridonidis, MD PhD, Jeffrey Szer, MBBS, Per Ljungman, MD PhD

Blood (2018) 132 (Supplement 1): 205.

https://doi.org/10.1182/blood-2018-99-110260

Published: 2018

Journal Articles

Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of Mitochondrial Vulnerability in Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 910.

https://doi.org/10.1182/blood-2018-99-114525

Published: 2018

Journal Articles

Chemogenomic Approach Unveils the Increased Susceptibility of RUNX1 -Mutated AML to Glucocorticoids

Laura Simon, BSc, MSc, Vincent-Philippe Lavallee, MD, Marie-Eve Bordeleau, PhD, Bernhard Lehnertz, PhD, Tara MacRae, Jalila Chagraoui, PhD, Jean-Francois Spinella, PhD, Geneviève Boucher, Thierry Bertomeu, PhD, Jasmin Coulombe-Huntington, PhD, Mike Tyers, PhD, Sébastien Lemieux, PhD, Anne Marinier, PhD, Josée Hébert, MD, Guy Sauvageau, MD PhD

Blood (2018) 132 (Supplement 1): 4675.

https://doi.org/10.1182/blood-2018-99-111030

Published: 2018

Journal Articles

High Expression of SPAG1 Is Associated with a Worse Clinical Outcome in Intermediate Risk Acute Myeloid Leukemia That Can be Partially Overcome By Hematopoietic Stem Cell Transplantation

Guillaume Richard-Carpentier, MD, Miriam Marquis, PhD, Guy Sauvageau, MD, PhD, Josee Hebert, MD

Blood (2018) 132 (Supplement 1): 2804.

https://doi.org/10.1182/blood-2018-99-113918

Published: 2018

NARROW

The XPO1-FOXC1-HOX Functional Axis Opens New Therapeutic Avenues to Treat DEK-NUP214 AML Patients

Identification of Acute Myeloid Leukemia Cell Surface Therapeutic Targets Using Single Cell RNA Sequencing Supported By Surface Proteomics

Identification of a Novel Cyclin K Degrader Molecule with Selective Anti-AML Activity

Disruption of Intracellular Metal Homeostasis As a Vulnerability in SF3B1 Mutated AML

Identification of Novel Antigens for Normal Karyotype Triple Mutated Acute Myeloid Leukemia

Identification of Novel Cell Surface Therapeutic Targets for KMT2A -Rearranged Acute Myeloid Leukemia

Targeting PLZF Enhances Glucocorticoid Sensitivity in Acute Myeloid Leukemia

IL1R1 Expression Predicts the Benefit from Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Intermediate-Risk Cytogenetics

Platelet EVs contain an active proteasome involved in protein processing for antigen presentation via MHC-I molecules

Efficacy, Toxicity and Cost of Venetoclax-Based Combinations for the Treatment of Acute Myeloid Leukemia: Real-World Evidence from a Canadian Academic Center

High frequency of germline RUNX1 mutations in patients with RUNX1 -mutated AML

A 9-Gene Expression Signature Identifies Patients with Core-Binding Factor Acute Myeloid Leukemia at High Risk of Relapse after Achieving Complete Remission

Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML

Genetic Characterization of ABT-199 Sensitivity in Human AML

Chemogenomic Profiling of Complex Karyotype AML Reveals a Novel Susceptibility to G2/M Checkpoint Inhibition Mediated By HMGA2 Overexpression

Apoptotic Blocks in Primary Non-Hodgkin B-Cell Lymphomas Identified By BH3 Profiling

Reduced Intensity Conditioned Sibling Transplantation Versus No Transplant in Intermediate or High Risk Acute Myeloid Leukemia: A Prospective Multi-Center Study in Patients 50-70 Years in First Complete Remission and with at Least One Potential Sibling Donor ( ClinTrialGov 00342316 )

Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of Mitochondrial Vulnerability in Acute Myeloid Leukemia

Chemogenomic Approach Unveils the Increased Susceptibility of RUNX1 -Mutated AML to Glucocorticoids

High Expression of SPAG1 Is Associated with a Worse Clinical Outcome in Intermediate Risk Acute Myeloid Leukemia That Can be Partially Overcome By Hematopoietic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only